<DOC>
	<DOCNO>NCT02616770</DOCNO>
	<brief_summary>To evaluate safety tolerability S-1226 compose perflubron ascend dos carbon dioxide ( 4 % , 8 % , 12 % CO2 ) administer 2 minute nebulisation healthy subject .</brief_summary>
	<brief_title>Phase1 , Placebo-Controlled , Randomized , Double-blind , Single-ascending Dose Study Healthy Subjects .</brief_title>
	<detailed_description>There 3 cohort ( 1 cohort per dose level ) . Each cohort include 12 subject ( 9 receive S-1226 3 receive match placebo ) . For dose level , sentinel group 2 subject dose ( 1 subject S-1226 , 1 subject placebo ) 24 hour prior dose rest study population . It may necessary repeat , modify ( decrease ) dose level , thus additional cohort 12 subject may enrol .</detailed_description>
	<mesh_term>Perflubron</mesh_term>
	<criteria>1 . Male female , nonsmoker , ≥18 ≤55 year age BMI &gt; 18.5 &lt; 30.0 . 2 . Healthy define : absence clinically significant illness surgery within 4 week prior dose . Subjects vomit within 24 hour predose carefully evaluate upcoming illness/disease . Inclusion predosing discretion Qualified Investigator ; absence clinically significant history neurological , endocrinal , cardiovascular , pulmonary , hematological , immunologic , psychiatric , gastrointestinal , renal , hepatic , metabolic disease ; absence clinically significant respiratory infection precede 6 week ; absence history malignancy within past five year , exception successfully treat nonmetastatic basal cell squamous cell carcinoma skin and/or localize carcinoma situ cervix ; absence clinically significant finding chest XRay screening . 3 . Steroidnaive ( i.e . volunteer currently topical systemic corticosteroid take oral injectable corticosteroid within 60 day prior study drug administration use inhaled/ophthalmic/nasal corticosteroid within 30 day prior study drug administration ) . 4 . Females childbearing potential sexually active male partner must willing use one follow acceptable contraceptive method throughout study 30 day : simultaneous use intrauterine contraceptive device without hormone release system place least 4 week prior study drug administration , male partner , condom ; simultaneous use diaphragm male partner , male condom spermicide start least 14 day prior study drug administration ; simultaneous use female condom start least 14 day prior study drug administration , male partner , condom spermicide ; sterile male partner ( vasectomize since least 6 month ) . 5 . Males subject vasectomized 6 month , sexually active nonsterile female partner must willing use one follow acceptable contraceptive method throughout study 30 day : simultaneous use condom , female partner , oral contraceptive , intrauterine contraceptive device place least 4 week prior study drug administration ; simultaneous use male condom , female partner , diaphragm spermicide ; simultaneous use male condom , female partner , female condom spermicide ; Sterile female partner include postmenopausal woman ( absence menses 12 month prior drug administration ) woman tubal ligation , hysterectomy , bilateral oophorectomy ( least 6 month prior drug administration ) . 6 . Capable consent . 7 . Subjects must normal lung function ( FEV1 ≥ 80 % predict FEV1/FVC &gt; 70 % ) . 1 . Any clinically significant abnormality abnormal laboratory test result find medical screening positive test hepatitis B , hepatitis C , HIV find medical screening . 2 . Positive urine drug screen urine cotinine test screening . 3 . Current cigarette smoker former smoker smoke history great 5 pack year stop smoke within 2 year precede enrolment study . For determination pack year , pack cigarette assume contain 20 cigarette . 4 . History significant allergic reaction ( e.g . angioedema , anaphylactic reaction ) . 5 . History panic disorder panic attack 6 . Positive pregnancy test screening . 7 . Any reason , opinion Investigator ( delegate ) , would prevent subject participate study . 8 . Clinically significant electrocardiogram ( ECG ) abnormalities vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) screening . 9 . History significant alcohol abuse within one year prior screen regular use alcohol within six month prior screen visit ( fourteen unit alcohol per week [ 1 Unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ] ) positive alcohol breath test screening . 10 . History significant drug abuse within one year prior screen use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] , crack ) within 1 year prior screen . 11 . Use investigational drug within 30 day ( 90 day biologics ) participation investigational study within 30 day prior dose . 12 . Use anticoagulant , immunosuppressive , regular use nonsteroidal antiinflammatory drug , use antiIgE medication , allergen specific immunotherapy within last 60 day . 13 . Use medication nonsteroidal topical product without significant systemic absorption : prescription medication ( one list previously ) within 14 day prior first dosing ; overthecounter product include natural health product ( e.g . food supplement herbal supplement ) within 7 day prior first dosing , exception occasional use acetaminophen ( 2 g daily ) ; depot injection implant drug within 3 month prior first dose . monoamine oxidase ( MAO ) inhibitor within 30 day prior first dosing . 14 . Donation blood within 7 day prior dose . Donation loss blood ( exclude volume drawn screen ) 50 mL 499 mL blood within 30 day , 499 mL within 56 day prior dose . 15 . Hemoglobin &lt; 128 g/L ( male ) &lt; 115 g/L ( female ) hematocrit &lt; 0.37 L/L ( male ) &lt; 0.32 L/L ( female ) screen . 16 . Breastfeeding subject . 17 . History wheeze exercise 18 . History previous medical diagnosis asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>